Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
95.54%
Operating Margin
37.12%
Net Margin
22.56%
Efficiency Metrics
Revenue per Expense Ratio
1.59
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
51.96%
Income Tax Rate
0.00%
EPS
0.8200000000
Balance Sheet Analysis
Current Ratio
4.68
Cash Ratio
3.53
Working Capital
$365.17M
Debt to Equity
0.23
Debt to Assets
11.81%
Equity Ratio
50.84%
Cash Flow Analysis
Operating Cash Flow Ratio
28.44%
Free Cash Flow Ratio
-51.11%
CapEx to Revenue
79.56%
Dividends Paid
$65.24M
Stock Buybacks
$4.76M
Total Shareholder Returns
$70.00M
Cash Position Change
-59.29%
Key Takeaways (2023 FY)
Revenue declined by 28.236668379097%, indicating potential market challenges
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
-28.24%
Net Income
143.98%
EPS
130.04%
Operating Income
253.05%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-16.47%
Operating Cash Flow
-11.02%
Free Cash Flow
112.44%
Balance Sheet Health
Assets
-67.70%
Debt
-92.28%
Book Value per Share
-46.94%
Inventory
100.00%
Shareholder Returns
Dividends per Share
-1.54%
Shares Outstanding
3.48%
Long Term Trends
3Y Revenue/Share
-50.81%
5Y Revenue/Share
-73.03%
3Y Dividend/Share
-74.00%
5Y Dividend/Share
-88.24%